Antibody-Drug Conjugates (ADC) represent next-generation anti-cancer therapeutics for the era of precision medicine.

ADCs combine antibodies that recognize cancer cells with powerful cell-destroying drugs (payloads). This structure maximizes therapeutic effects while minimizing damage to normal cells by selectively binding to cancer cells and delivering the drug. They are particularly gaining attention as a new alternative for patients with intractable solid tumors and blood cancers that are difficult to treat with conventional cancer therapies.

One of the rapidly growing companies developing next-generation ADC platform technology is LigaChem Biosciences (CEO Yongju Kim). The company has secured proprietary technology that overcomes existing ADC pharmaceuticals' unmet needs and limitations, earning recognition for its more innovative ADC development capabilities. LigaChem Biosciences is strengthening its competitiveness in Chemistry, Manufacturing, and Controls (CMC) to mass-produce consistent, high-quality pharmaceuticals that comply with global Good Manufacturing Practice (GMP) regulatory standards.

Currently, LigaChem Biosciences has more than 25 ADC pipelines targeting primary cancer cell targets, including HER2, TROP2, ROR1, and B7-H4, with some showing superior results compared to competing drugs in global clinical trials. To secure more than five commercialized new drugs by 2030, the company is accelerating its leap toward becoming a global 'ADC Big Biotech.'

* CMC (Chemistry, Manufacturing, and Controls): Addresses the chemical properties, manufacturing processes, and quality control systems of pharmaceuticals, ensuring products are safe and effective.
* GMP (Good Manufacturing Practice): Refers to the quality control standards that pharmaceutical manufacturers must adhere to throughout the entire process from raw material receipt to pharmaceutical release, from manufacturing to distribution.